Perspective Therapeutics, Inc. CATX 深 沪
已收盘 05-08 16:00:00 美东时间
3.76
+0.160
+4.44%
华盛通- 最 高3.795
- 今 开3.60
- 成交量 79.50万股
- 最 低 3.5796
- 昨 收 3.60
- 总市值 4.29亿
- 52周最高 6.16
- 市盈率 静 --
- 换手率 0.70%
- 52周最低 1.955
- 委 比 -10.79%
- 总股本 1.14亿
- 历史最高 37.90
- 量 比 0.35
- 振 幅 5.98%
- 历史最低 1.60
- 每 手 1
- 风险率 0.92%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多美股大行评级 | Stifel上调Lumentum控股目标价从800美元升至1100美元；Pinterest、先进能源工业、安森美半导体、莱迪思半导体、V2X等获多家大行上调目标价
今日重点评级关注：Piper Sandler：维持Aclaris Therapeutics"超配"评级，目标价从7美元升至11美元；Evercore ISI集团：维持BioMarin Pharmaceutical"跑赢大市"评级，目标价从110美元升至120美元
05-06 11:29
BTIG Reiterates Buy on Perspective Therapeutics, Maintains $14 Price Target
BTIG analyst Jeet Mukherjee reiterates Perspective Therapeutics (AMEX:CATX) with a Buy and maintains $14 price target.
05-05 19:42
美股大行评级 | 大摩上调Lumentum目标价从595美元升至710美元；康宁、道富银行、Ally Financial获多家机构上调目标价
今日重点评级关注：Canaccord Genuity：维持Vertical Aerospace"买入"评级，目标价从9.5美元升至10.5美元；Canaccord Genuity：维持AtaiBeckley Inc."买入"评级，目标价从14美元升至15美元
04-21 11:25
Perspective Therapeutics Reports 72% Of Patients Alive Without Disease Progression In Early Cancer Trial, Says 43% Of Patients Show Tumor Response With New Radiotherapy Treatment
Perspective Therapeutics, Inc. ("Perspective" or the "Company) (NYSE:CATX), a radiopharmaceutical development company pioneering advanced treatments for cancers throughout the body, today announced updated interim
04-20 18:12
美股大行评级 | 瑞穗上调MongoDB至"跑赢大市"，目标价从290美元升至325美元；麦格理下调小鹏评级至"中性" 目标价从24美元降至19美元
今日重点评级关注：HC Wainwright & Co.：维持Perspective Therapeutics"买入"评级，目标价从12美元升至13美元；Litchfield Hills：维持Star Equity Holdings"买入"评级，目标价从21美元升至28美元
03-24 10:07
美股大行评级 | 超多下调！露露乐蒙、Oklo、腾讯音乐、Docusign、BOBS、Bicycle、Academy Sports等遭多家大行下调目标价
今日重点评级关注：花旗：维持Candel Therapeutics"买入"评级，目标价从22美元升至26美元；Chardan Capital：维持CervoMed"买入"评级，目标价从15美元升至21美元
03-19 14:31
美股大行评级 | 摩根大通上调哔哩哔哩至"超配"，目标价从27美元升至35美元；Rhythm遭花旗、大摩等多家机构下调目标价
今日重点评级关注：韦德布什：维持Black Diamond Therapeutic"跑赢大市"评级，目标价从13美元升至14美元；花旗：维持Olema Pharmaceuticals"买入"评级，目标价从60美元升至62美元
03-18 10:48
Perspective Therapeutics To Present Updated [212Pb]VMT-α-NET Data At AACR 2026
Perspective Therapeutics, Inc. ("Perspective" or the "Company") (NYSE:CATX), a radiopharmaceutical development company pioneering advanced treatments for cancers throughout the body, today announced that updated
03-18 04:47
BTIG Reiterates Buy on Perspective Therapeutics, Maintains $14 Price Target
BTIG analyst Jeet Mukherjee reiterates Perspective Therapeutics (AMEX:CATX) with a Buy and maintains $14 price target.
03-17 18:40
Perspective Therapeutics Q4 EPS $(0.51) Misses $(0.36) Estimate, Sales $43.000K Miss $215.615K Estimate.
Perspective Therapeutics (AMEX:CATX) reported quarterly losses of $(0.51) per share which missed the analyst consensus estimate of $(0.36) by 42.06 percent. This is a 15 percent increase over losses of $(0.60) per share
03-17 04:10
